BIOXEE is an easy to use and low cost device with a breakthrough method for non-invasive measurement of heart rate waves and arterial stiffness. The operation of BIOXEE is based on self-learning algorithms, which allow for quick and precise determination of the risk of developing vascular disease in a patient.

NON-INVASIVENESS

achieved through the use of the latest generation of polymer piezoelectric sensors

SIMPLE HANDLING

testing is performed by lower level medical staff

SPEED

test lasting 10 minutes

COMPETITIVE PRICE

much cheaper than Doppler ultrasound and other pulse wave devices

DIGITAL INTERPRETATION OF RESULTS

with convenient and secure storage and transfer of data from the cloud

MULTIPOINT MEASUREMENT

crucial for correct analysis

Bioxee

uses the experience of the EMBIQ team, gathered during the construction of KTG – a mobile cardiotocogram.
Thanks to this device, it is possible to perform prenatal tests (monitoring the fetus’ heart function, its movements and uterine contractions) without leaving home and without the assistance of a doctor.

The BIOXEE is a first-time contact device.

No specialist knowledge is needed to operate it. Tests using it can be performed by medical personnel at a lower level, already after one day of training. Only 10 minutes of operation of the device is sufficient to obtain an accurate result.

Koszt zakupu BIOXEE to zaledwie ułamek ceny, którą trzeba zapłacić za dopplerowskie USG. BIOXEE pod tym względem jest konkurencyjne również w stosunku do tradycyjnych urządzeń służących badaniu tętna. Kolejne oszczędności generowane są przez szybkość działania urządzenia, jego mobilność i przesyłanie wyników przez sieć. W konsekwencji skracane są kolejki do lekarza, zmniejsza się ilość wizyt, zaś jakość życia pacjenta ulega znacznej poprawie.

Introducing this easy-fast and low-cost diagnostic method to the market will open the way to:

to estimate arterial stiffness, which has now taken on great importance in assessing cardiovascular risk

run screening tests on a large population of those potentially prone to developing Diabetic Foot Syndrome – over 40 years old patients with diabetes

analysis of measurement data completed with disease classification in case of disease in the cardiovascular system (the consent of the Bioethics Committee for two-year clinical trials – first results are available)

BIOXEE uses the concept of the Internet of Things (IoT) in a practical dimension, especially in the area of intelligent health networks. The data collected by the device allows for the spontaneous creation of disease detection algorithms and a convenient and safe transfer of research results to the cloud.

Cardiovascular diseases contribute to the deaths of over 4 million Europeans every year. The guilty of this state of affairs are also too late and too slow to make a diagnosis. Equipped with intelligent software and based on a user-friendly design, BIOXEE is an effective weapon in the fight against this problem.

We are flying to Dubai!

Teleinfomed takes part in an economic mission to Dubai, United Arab Emirates, organized by the Marshal’s Office of the Lubelskie Voivodship in Lublin between 27-31.01.2020r. The project “Economic Marketing of Lubelskie Voivodship II" is co-financed by the European Regional Development Fund under the Regional Program Operational Voivodship Lubelskie  2014-2020, Priority Axis 3, Competitiveeness of Enterprises, measure 3.6 Economic Marketing.